Argenx turning cash cow into global commercialization engine

Argenx is leveraging strong investor interest in mid-cap biotechs to launch a pipeline with a global footprint, built around its autoimmune candidate efgartigimod, and is lining up two additional first-in-class clinical programs  to quickly follow suit.

The Belgian biotech has become one of the weather vanes of the European sector. Under the leadership of co-founder and CEO Tim Van Hauwermeiren, argenx SE (Euronext:ARGX; NASDAQ:ARGX) has grown from a sub-$200 million valuation at its Euronext IPO in July 2014 to a $20 billion global biopharma company that raised nearly $1.2 billion in a follow-on earlier this month...